Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (29)

B-04Nikolaos Alimpertis

The estimates for the absorption rate constant in pharmacokinetics and pharmacometrics are wrong: A new era based on the finite absorption time concept rises

Wednesday 9:00-9:20

B-05Robin Chaux

Meta-analysis of parameter estimates of non-linear mixed effect models using Approximate Bayesian Computation: application to population pharmacokinetics

Wednesday 9:20-9:40

B-06Mohamed Gewily

A Semi Parametric Method for the Estimation of End of Treatment Effect

Wednesday 9:40-10:00

B-09Kristin Karlsson

Paediatric Extrapolation – Opportunities and Challenges

Wednesday 11:30-11:50

B-10Italo Poggesi

Extrapolating treatment to children less than 6 years old: the successful story of velmanase alfa in alpha-mannosidosis

Wednesday 11:50-12:10

B-11Bart van Lieshout

Population pharmacokinetic analysis of guanabenz in children with Vanishing White Matter: Evaluating scaling adult drug safety and pharmacokinetics data

Wednesday 12:10-12:30

B-14Nadia Terranova and Uri Nahum

Artificial Intelligence and Machine Learning for Next-Generation Model-Informed Precision Medicine: A Tutorial on Practical Applications and Pitfalls

Wednesday 14:00-14:50

B-16Antari Khot

Do tree-based machine learning methods outperform Cox regression for progression-free survival prediction in mobocertinib treated lung cancer patients?

Wednesday 14:50-15:10

B-17Ana Victoria Ponce Bobadilla

Benefits of integrating machine learning with clinical pharmacology principles for predictive pharmacokinetic modeling

Wednesday 15:10-15:30

B-21Alzahra Hamdan

Item Response Theory Analysis of the Scale for the Assessment and Rating of Ataxia in Autosomal Recessive Cerebellar Ataxias

Wednesday 17:05-17:25

B-22Alessio Paris

An age-dependent QSP model of Nf trafficking to optimize treatment in neurodegenerative diseases

Wednesday 17:25-17:45

C-02Conor O'Hanlon

A framework for drug pharmacokinetics during cardiopulmonary bypass

Thursday 8:30-8:55

C-03Alexander Janssen

A generative and causal pharmacokinetic model for haemophilia A: towards an unified model for all factor VIII concentrates.

Thursday 8:55-9:20

C-04Alessandro De Carlo

Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat

Thursday 9:20-9:45

C-05Alexandra Lavalley-Morelle

Joint modeling of biomarkers dynamics and survival with competing risks to predict the prognostic of patients hospitalized with severe infectious diseases

Thursday 9:45-10:10

C-09Iñaki F. Trocóniz

Modeling the dynamics of anti-drug antibodies in cancer patients treated with oncolytic virus in monotherapy or in combination with immune check- point inhibitors

Thursday 11:45-12:05

C-10Quentin Clairon

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2 vaccine

Thursday 12:05-12:25

C-13Alexandra Snyder

Current and future applications of circulating tumor DNA (ctDNA) to oncology drug development

Thursday 13:55-14:40

C-15Yomna Nassar

A joint tumour dynamics and C-reactive protein turnover model to identify early longitudinal prognostic predictors of overall survival in advanced non-small cell lung cancer patients

Thursday 14:40-15:00

C-16Anna Kondic

The combined use of propensity score matching and a joint tumor growth dynamics (TGD) – Overall Survival (OS) model to benchmark the efficacy of new treatments for advanced renal cell carcinoma (RCC)

Thursday 15:00-15:20

C-20Freya Bachmann

Computing Optimal Drug Dosing with Constraints on Model States in NONMEM

Thursday 16:55-17:15

C-21Dominic Bräm

Neural ODE structures based on pharmacokinetic principles

Thursday 17:15-17:35

C-22Zhonghui Huang

Development and exploration of exhaustive, stepwise, and heuristic algorithms for automated population pharmacokinetic modelling

Thursday 17:35-17:55

D-02Joey Leung

Virtual population analysis of a Quantitative Systems Pharmacology (QSP) model of atopic dermatitis (AtD) to evaluate AtD treatments

Friday 9:15-9:35

D-03Natalia Riva

Expanding a quantitative systems pharmacology (QSP) modeling framework for acute Hepatitis B to characterize chronic infection

Friday 9:35-9:55

D-04Robin Michelet

Development and Application of a Minimal Physiology-based Pharmacokinetics Modelling Framework to Predict Tumor Penetration and Receptor Occupancy.

Friday 9:55-10:15

D-08Martin Bergstrand

Application relevant shrinkage metrics

Friday 10:55-11:15

D-09Sarah Baklouti

Multivariate Exact Discrepancy : a new tool for PK/PD model evaluation

Friday 11:15-11:35

D-10Stefanie Hennig

Considerations when deriving time-averaged exposure for censored subjects for logistic regression exposure-response analyses

Friday 11:35-11:55